Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,395 questions in 172 reviews · Gut
current versionsNo studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Clinical remission (9 weeks) · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 4.27 [1.07, 16.96] | 1 study · 31 participants | Very low |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Clinical improvement (Mayo score) (9 weeks) · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 2.67 [1.06, 6.7] | 1 study · 31 participants | Very low |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Quality of life · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Total adverse events (9 weeks) · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 1.71 [0.72, 4.06] | 1 study · 31 participants | Very low |
Corticosteroids vs placebo Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.74 [1.08, 2.8] | 6 studies · 583 participants | Low |
Corticosteroids vs placebo Histological improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 4.58 [1.66, 12.62] | 3 studies · 280 participants | Moderate |
Leukotriene receptor antagonist vs placebo Clinical improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Histological improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Histological improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Endoscopic improvement (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Endoscopic improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Leukotriene receptor antagonist vs placebo Withdrawals due to adverse events at 26 weeks · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 2.1 [0.21, 21.39] | 1 study · 41 participants | Very low |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement at 12 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.19 [0.37, 3.77] | 1 study · 39 participants | Very low |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Histological improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 3 studies · 269 participants | Moderate |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg Withdrawals due to adverse events at 8 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.63 [0.12, 3.38] | 1 study · 39 participants | Very low |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement at 12 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 2.14 [0.79, 5.79] | 1 study · 39 participants | Very low |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg Withdrawals due to adverse events at 8 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.32 [0.04, 2.79] | 1 study · 39 participants | Very low |
Corticosteroids vs placebo Endoscopic improvement at study endpoint (dichotomous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Clinical improvement at (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Histological improvement at 12 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.56 [0.23, 1.37] | 1 study · 40 participants | Very low |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Mepolizumab 10 mg/kg vs mepolizumab 2.5 mg/kg Withdrawals due to adverse events at 8 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 2 [0.2, 20.33] | 1 study · 40 participants | Very low |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Clinical improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Histological improvement at 8 weeks (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 64 participants | Very low |
Corticosteroids vs placebo Endoscopic improvement (continuous) · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 2 studies · 240 participants | Very low |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Histological improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide Withdrawals due to adverse events at 26 weeks · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs placebo Withdrawals due to adverse events 12 to 50 weeks · inactive EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 0.37 [0.16, 0.87] | 3 studies · 280 participants | Low |
Biologics vs placebo Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 1.14 [0.85, 1.52] | 5 studies · 410 participants | Low |
Biologics vs placebo Clinical improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 7 studies · 387 participants | Moderate |
Biologics vs placebo Histological improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | RR 6.73 [2.58, 17.52] | 8 studies · 925 participants | Moderate |
Biologics vs placebo Histological improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 6 studies · 370 participants | Very low |
Biologics vs placebo Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 1 study · 11 participants | Low |
Corticosteroids vs placebo Clinical improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | 5 studies · 475 participants | Low |